Navigation Links
StromAb, First-In-Class Antibody Dissolves Thrombus In ACUTE Stroke & Cardiovascular Disease, In Production Phase I Clinical Trials
Date:11/21/2013

(PRWEB) November 21, 2013

Translational Sciences Inc. announces that StromAb is in production on Phase I Clinical Trials. Production began after completing highly successful pre-clinical development studies showing exceptional efficacy and safety in multiple disease models.

StromAb is a first-in-class antibody providing immediate safe dissolution of ACUTE blood clots that cause > 2 million cases of ischemic stroke, venous thrombosis, pulmonary embolism, heart attack and acute peripheral vascular ischemia in the U.S. alone.

Translational Sciences Inc. holds exclusive licensing rights with Massachusetts General Hospital & Harvard University.

Distinct from existing agents or agents in development: StromAb occupies a different therapeutic space, than anticoagulants (e.g., heparins, or direct thrombin or factor Xa inhibitors etc.). StromAb rapidly dissolves clots in ACUTE cardiovascular diseases; anticoagulants inhibit blood clot formation but do not dissolve clots.

However, StromAb is also compatible with anticoagulants in the therapeutic process.

StromAb was selected by NIH for therapeutic development grants. StromAb is supported by multiple patents and patent actions.

Translational Sciences is currently exploring partnerships for future clinical trials.

Experts Have Commented:

  •     “The striking preclinical profile of StroMAb .…predicts both a significant improvement in efficacy and major reductions in risk….could revolutionize the treatment of ischemic stroke.”
  •     “This is a highly significant project that addresses the most important unmet medical need for safe drugs to treat acute thrombotic diseases with poor prognosis (stroke, heart attack, pulmonary embolism, arterial thrombosis)."
  •     “These antibodies have the potential to dramatically change the course of treatment of thromboembolic stroke and other ischemic diseases.”

Translational Sciences, Inc. is a privately held biopharmaceutical company that translates scientific insights into first-in-class, biologic agents for cardiovascular diseases.

Interested parties may contact Translational Sciences at 901-274-4506 or email David Pedersen, dpedersen(at)translationalsciences(dot)com

Read the full story at http://www.prweb.com/releases/2013/11/prweb11351177.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. TesoRx and CoreRx Announce Joint Venture to Manufacture First-in-Class Oral Testosterone Drug
2. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
3. Labome: The Gateway to the Perfect Antibody -- Labome Antibody Review Database Has Now Reached 10,000 Peer-Reviewed Formal Publications
4. Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit
5. Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment
6. Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
7. GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research
8. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
9. Goodwin Biotechnology and Coldstream Laboratories Announce a Collaboration to Develop and Manufacture Cytotoxic Antibody Drug Conjugates
10. Scripps Research Institute Scientists Find Antibody that Transforms Bone Marrow Stem Cells Directly into Brain Cells
11. Antibody Technologies and Attrition Rates -- an industry analysis 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of ... board-certified in surgery and surgery of the hand by the National Board of ... to going above and beyond in his pursuit of providing the most comprehensive, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lady had been battling arthritis since the ... in her left knee. Lady’s owner Hannah sought the help of Dr Jeff Christiansen ... to repair her cruciate ligament and help with the pain of Lady’s arthritis. Dr ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an integrated wealth management ... The Future of San Diego Life Science event at the Estancia La Jolla Resort ... the event with speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and ...
(Date:5/23/2016)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of $0.24 per share ... stockholders of record as of the close of business on ... approval of the Board of Directors and may be adjusted ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
(Date:3/15/2016)... March 15, 2016 --> ... by Transparency Market Research "Digital Door Lock Systems Market - ... - 2023," the global digital door lock systems market in ... 2014 and is forecast to grow at a CAGR of ... small and medium enterprises (MSMEs) across the world and high ...
Breaking Biology News(10 mins):